Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

University of Toronto

$100,000.00

Kallikrein-related serine proteases as therapeutic targets for cancer

EF 2008-09

Résumé
Aberrant proteolysis is associated with many diseases, including cancer. Already, many Pharmaceutical companies are targeting proteases for developing new therapeutics for cancer and other diseases. Our laboratory is leading research related to a family of serine proteases called "human tissue kallikreins" (KLKs). These KLKs are 15 extracellular proteases which appear to be closely linked to tumour progression. We thus believe that KLKs represent a new, and promising, cancer drug target. In this application, we propose to pre-clinically validate a few members of the kallikrein family as therapeutic targets for treatment of cancer. We will use quantitative proteomics, in-vitro cell-based assays and animal xenograft models to increase our understanding of kallikrein pathophysiology in breast cancer. This investigation may lead to development of novel therapies for breast and other cancers.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
355696-2007
Name nom
Diamandis, Eleftherios
Department département
Laboratory Medicine and Pathobiology
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2007
Award amount
1e+05
Program id
CRDPJ
Program nane en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
6401
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pathology
Research subject fr
Pathologie
Partie
1
Nb partie
3
Application title
Kallikrein-related serine proteases as therapeutic targets for cancer
Keyword
NA
Application summary
Aberrant proteolysis is associated with many diseases, including cancer. Already, many Pharmaceutical companies are targeting proteases for developing new therapeutics for cancer and other diseases. Our laboratory is leading research related to a family of serine proteases called "human tissue kallikreins" (KLKs). These KLKs are 15 extracellular proteases which appear to be closely linked to tumour progression. We thus believe that KLKs represent a new, and promising, cancer drug target. In this application, we propose to pre-clinically validate a few members of the kallikrein family as therapeutic targets for treatment of cancer. We will use quantitative proteomics, in-vitro cell-based assays and animal xenograft models to increase our understanding of kallikrein pathophysiology in breast cancer. This investigation may lead to development of novel therapies for breast and other cancers.